AMENDED DEVELOPMENT AND LICENSE AGREEMENT By and between ALMIRALL, S.A. and ASLAN PHARMACEUTICALS PTE. LTD. Dated: December 21, 2015Development and License Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
This AMENDED DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), dated as of December 21, 2015 (“Effective Date”), is entered by and between ALMIRALL, S.A. (“ALMIRALL”), a Spanish corporation having its principal offices at Ronda de General Mitre, 151, 08022 Barcelona, Spain, and ASLAN PHARMACEUTICALS Pte. Ltd. (“ASLAN”), a Singapore corporation having its principal offices at 10A Bukit Pasoh Road, Singapore 089824. ALMIRALL and ASLAN shall be referred to individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • England and Wales
This License Agreement (this “Agreement”), entered into as of January 3rd, 2018 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having offices at 3200 Walnut Street, Boulder, Colorado 80301, and ASLAN Pharmaceuticals Pte. Ltd., a Singapore corporation, with offices at 83 Clemenceau Avenue #12-03 UE Square, Singapore 239920.
DATED THIS 10th DAY OF OCTOBER 2016 Between NANYANG TECHNOLOGICAL UNIVERSITY And ASLAN PHARMACEUTICALS PTE LTD LICENSING AND RESEARCH COLLABORATION AGREEMENTAnd Research Collaboration Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
LICENCE AGREEMENT BETWEEN CSL LIMITED ABN 99 051 588 348 AND ASLAN Pharmaceuticals Pte LtdLicence Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • England
Now, therefore, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
